Rajeev I Desai1, Michelle R Doyle2, Sarah L Withey2, Jack Bergman2. 1. Preclinical Pharmacology Laboratory, McLean Hospital/Harvard Medical School, 115 Mill Street, Belmont, MA, 02478, USA. rdesai@mclean.harvard.edu. 2. Preclinical Pharmacology Laboratory, McLean Hospital/Harvard Medical School, 115 Mill Street, Belmont, MA, 02478, USA.
Abstract
RATIONALE: Recent studies in rodents suggest that non-nicotine constituents of tobacco smoke (e.g., minor tobacco alkaloids) may promote tobacco consumption-either through their own pharmacological effects or by augmenting the effects of nicotine. However, there is scant information on the behavioral pharmacology of minor tobacco alkaloids in primate species. OBJECTIVE: The present studies were conducted to determine whether the minor tobacco alkaloids nornicotine, anabasine, anatabine, myosmine, and cotinine exhibit nicotine-like behavioral effects in squirrel monkeys. METHODS: Initial experiments were conducted to determine the effects of nicotine (0.032-1.0 mg/kg) and the minor tobacco alkaloids nornicotine (1-1.8 mg/kg), anabasine (0.1-1.0 mg/kg), anatabine (10-32 mg/kg), myosmine (0.32-1.8 mg/kg), and cotinine (10-180 mg/kg) on food-maintained performance (n = 4). Next, the ability of tobacco alkaloids to substitute for the α4β2-selective nicotinic agonist (+)-epibatidine in drug discrimination experiments was evaluated in a separate group of monkeys (n = 4). RESULTS: Results show that nicotine and each minor tobacco alkaloid except cotinine (a) produced dose-related decreases in food-maintained responding; (b) substituted for (+)-epibatidine and, in additional experiments, produced additive effects when combined with nicotine; (c) induced emesis or tremor at doses that reduced food-maintained responding and had (+)-epibatidine-like discriminative-stimulus effects; and (d) based on correlation with reported receptor binding affinities, likely produced their behavioral effects through α4β2 receptor mechanisms. CONCLUSION: Selected minor tobacco alkaloids have nicotinic-like effects that may contribute to tobacco consumption and addiction.
RATIONALE: Recent studies in rodents suggest that non-nicotine constituents of tobacco smoke (e.g., minor tobaccoalkaloids) may promote tobacco consumption-either through their own pharmacological effects or by augmenting the effects of nicotine. However, there is scant information on the behavioral pharmacology of minor tobaccoalkaloids in primate species. OBJECTIVE: The present studies were conducted to determine whether the minor tobaccoalkaloidsnornicotine, anabasine, anatabine, myosmine, and cotinine exhibit nicotine-like behavioral effects in squirrel monkeys. METHODS: Initial experiments were conducted to determine the effects of nicotine (0.032-1.0 mg/kg) and the minor tobaccoalkaloidsnornicotine (1-1.8 mg/kg), anabasine (0.1-1.0 mg/kg), anatabine (10-32 mg/kg), myosmine (0.32-1.8 mg/kg), and cotinine (10-180 mg/kg) on food-maintained performance (n = 4). Next, the ability of tobaccoalkaloids to substitute for the α4β2-selective nicotinic agonist (+)-epibatidine in drug discrimination experiments was evaluated in a separate group of monkeys (n = 4). RESULTS: Results show that nicotine and each minor tobacco alkaloid except cotinine (a) produced dose-related decreases in food-maintained responding; (b) substituted for (+)-epibatidine and, in additional experiments, produced additive effects when combined with nicotine; (c) induced emesis or tremor at doses that reduced food-maintained responding and had (+)-epibatidine-like discriminative-stimulus effects; and (d) based on correlation with reported receptor binding affinities, likely produced their behavioral effects through α4β2 receptor mechanisms. CONCLUSION: Selected minor tobaccoalkaloids have nicotinic-like effects that may contribute to tobacco consumption and addiction.
Entities:
Keywords:
Anabasine; Anatabine; Drug discrimination; Epibatidine; Food-maintained behavior; Minor tobacco alkaloids; Myosmine; Nicotine; Nonhuman primates; Nornicotine
Authors: Dorothy K Hatsukami; Kenneth A Perkins; Mark G Lesage; David L Ashley; Jack E Henningfield; Neal L Benowitz; Cathy L Backinger; Mitch Zeller Journal: Tob Control Date: 2010-10 Impact factor: 7.552
Authors: Andrew C Harris; Laura Tally; Peter Muelken; Andrew Banal; Clare E Schmidt; Qing Cao; Mark G LeSage Journal: Drug Alcohol Depend Date: 2015-06-09 Impact factor: 4.492
Authors: Julie A Marusich; Mahesh Darna; A George Wilson; Emily D Denehy; Amanda Ebben; Agripina G Deaciuc; Linda P Dwoskin; Michael T Bardo; Timothy W Lefever; Jenny L Wiley; Chad J Reissig; Kia J Jackson Journal: Eur J Pharmacol Date: 2017-08-26 Impact factor: 4.432
Authors: Andrew C Harris; Peter Muelken; Yayi Swain; Mary Palumbo; Vipin Jain; Maciej L Goniewicz; Irina Stepanov; Mark G LeSage Journal: Drug Alcohol Depend Date: 2019-08-01 Impact factor: 4.492
Authors: Andrew C Harris; Peter Muelken; John R Smethells; Katrina Yershova; Irina Stepanov; Thao Tran Olson; Kenneth J Kellar; Mark G LeSage Journal: Drug Alcohol Depend Date: 2018-02-01 Impact factor: 4.492